PMV Pharmaceuticals, Inc. (PMVP) company profile
Close on Nov 17, 2026Market cap $65.22MP/E –Yield –
About PMV Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
PMV Pharmaceuticals is a precision oncology company that discovers and develops small molecule, tumor-agnostic therapies targeting mutant p53 proteins to restore their normal tumor-suppressing function. The company's lead product candidate is rezatapopt, an orally administered small molecule designed to structurally correct misfolded p53 proteins carrying the Y220C mutation. Rezatapopt aims to treat patients with advanced or metastatic solid tumors harboring this mutation, including ovarian, endometrial, breast, non-small cell lung, colorectal, and pancreatic cancers.
The company operates in the United States and conducts clinical evaluations, including its pivotal PYNNACLE clinical trial. Its principal executive offices and headquarters are located in Princeton, New Jersey.
Summary of the business section of PMV Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PMV Pharmaceuticals, Inc.
- Headquarters
- Princeton, NJ
- Address
- 400 Alexander Park Drive, Suite 301 08540
- Phone
- (609) 642-6670
- Website
- pmvpharma.com
- Employees
- 54, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PMVP
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2020
- Shares outstanding
- 53M, Aug 14, 2026
- Public float
- $53.44M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1699382
- CUSIP
- 69353Y103
- ISIN
- US69353Y1038
- FIGI
- BBG007NM47G3
- Share class FIGI
- BBG007NM4862
- EIN
- 46-3218129
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Henry Mack | President and CEO, Director | 904,691 |
| Robert Ticktin | General Counsel & COO | 98,695 |
| Deepika Jalota | Chief Development Officer | 89,959 |
| Michael Carulli | Chief Financial Officer | 73,848 |
| Matthew Joseph Eckler | Director | – |
| Laurie Stelzer | Director | – |
| Carol Giltner Gallagher | Director | – |
| Charles M. Baum | Director | – |
| Arnold J. Levine | Director | 409,842 |
| Kirsten Flowers | Director | – |
| Richard A. Heyman | Director | 558 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.67M | $958.18K | $898.20K | $14 | – |
| FY2024 | $4.76M | $2.17M | $1.65M | $7 | – |
| FY2023 | $2.21M | $513.65K | $1.18M | $13 | – |
| FY2022 | $3.58M | -$519.25K | $2.13M | $38 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| David H. Mack, Ph.D. President, Chief Executive Officer and Director | $628.46K | $752.32K | $284.41K | $1.67M | -65% |
| Deepika Jalota, Pharm.D. Chief Development Officer | $478.43K | $282.12K | $174.64K | $935.19K | -52% |
| Robert Ticktin General Counsel & Chief Operating Officer | $450.00K | $249.21K | $162.00K | $861.21K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 25, 2020
- Offer price
- $18.00
- Securities offered
- 11,765,000
- Gross proceeds
- $211.77M
- Exchange
- Nasdaq
- First trading day
- Sep 25, 2020
- First-day close
- $37.51+108.4%
- Lock-up ends (est.)
- Mar 24, 2021
“The initial public offering price is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 6, 2026 , we had 54 full-time employees, including 18 employees with Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 25, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 21, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?